Diabetes Research
To learn more about diabetes and ongoing clinical trials in this area, visit our Diabetes Research page.
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo.
Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
Participants with body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
Are males or females not of childbearing potential
Participants with acute proliferative retinopathy requiring active treatment within 3 months of screening
Participants who have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
Participants who received systemic or inhaled glucocorticoid therapy
Women of childbearing potential
To learn more about diabetes and ongoing clinical trials in this area, visit our Diabetes Research page.
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.